Increase in Papillary Thyroid Cancer Incidence Is Accompanied by Changes in the Frequency of the BRAF V600E Mutation: A Single-Institution Study.

BACKGROUND Thyroid cancer (TC) has one of the fastest increasing incidences worldwide and primarily involves papillary thyroid cancer (PTC). The BRAF(V600E) mutation is the most common genetic alteration identified in PTC. There are few data concerning an association between the rising incidence of PTC and the increasing prevalence of BRAF-positive cases. Environmental factors such as iodine intake may be responsible for the changing molecular features of PTC. The aim of this study was to evaluate probable variations in the frequency of the BRAF(V600E) mutation in PTC that were diagnosed at a single institution over 14 years in Poland, a country with a demonstrated improvement in iodine supplementation in the early 21st century. METHODS Time-dependent trends in the prevalence of the BRAF(V600E) mutation during three time periods (2000-2004, 2005-2009, and 2010-2013) were analyzed. The BRAF mutation was genotyped using direct sequencing, allele-specific polymerase chain reaction (PCR), and real-time PCR in 723 unselected cases of PTC that were diagnosed in 2000-2013. Trends in the clinicopathologic characteristics of all PTCs and BRAF(V600E)-positive PTCs were also analyzed. RESULTS The proportion of PTCs with mutations significantly increased over the study period (54.8% vs. 70.6%; p = 0.001). The median tumor size of all and BRAF-positive tumors decreased (p = 0.008 and p = 0.001, respectively) and correlated with an increase in the proportion of all and mutated microcarcinomas (p = 0.003 and p = 0.003, respectively). A decrease in all and mutated tumors between 2 and 4 cm was also observed (p = 0.002 and p = 0.006, respectively). A significant decrease in tumors ≥ 4 cm in size was only observed in BRAF-positive cases (p = 0.017). The proportion of classic PTC with BRAF(V600E) mutation was observed to increase (57.6% vs. 74.4%; p = 0.001) and was stable for the follicular variant of PTC (p = 0.336). CONCLUSIONS The prevalence of the BRAF(V600E)mutation increased significantly in PTCs diagnosed in the authors' institution. Improved detection and several causative factors, most likely environmental and changes in iodine intake, may contribute to the increasing occurrence of TC.

[1]  S. Piana,et al.  Time to re‐consider the meaning of BRAF V600E mutation in papillary thyroid carcinoma , 2015, International journal of cancer.

[2]  E. Chmielik,et al.  The Risk of Relapse in Papillary Thyroid Cancer (PTC) in the Context of BRAFV600E Mutation Status and Other Prognostic Factors , 2015, PloS one.

[3]  Eva Negri,et al.  Thyroid cancer mortality and incidence: A global overview , 2015, International journal of cancer.

[4]  Markku Miettinen,et al.  Detection of the BRAF V600E Mutation in Colon Carcinoma: Critical Evaluation of the Imunohistochemical Approach , 2014, The American journal of surgical pathology.

[5]  J. Sygut,et al.  The BRAFV600E mutation in papillary thyroid microcarcinoma: does the mutation have an impact on clinical outcome? , 2014, Clinical endocrinology.

[6]  A. Toniato,et al.  The role of BRAF(V600E) mutation as poor prognostic factor for the outcome of patients with intrathyroid papillary thyroid carcinoma. , 2014, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[7]  A. Miyauchi,et al.  BRAFV600E Mutation Analysis in Papillary Thyroid Carcinoma: Is it Useful for all Patients? , 2014, World Journal of Surgery.

[8]  J. Lubin,et al.  The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations. , 2014, The Journal of clinical endocrinology and metabolism.

[9]  T. Tosteson,et al.  The increasing incidence of thyroid cancer: the influence of access to care. , 2013, Thyroid : official journal of the American Thyroid Association.

[10]  S. Hong,et al.  Detection of BRAF V600E mutation with thyroid tissue using pyrosequencing: comparison with PNA-clamping and real-time PCR. , 2013, American Journal of Clinical Pathology.

[11]  J. Zhuge,et al.  Sensitive detection of BRAF V600E mutation by Amplification Refractory Mutation System (ARMS)-PCR , 2013, Biomarker Research.

[12]  M. Karbownik-Lewińska,et al.  Oxidative damage to macromolecules in the thyroid - experimental evidence , 2012, Thyroid Research.

[13]  D. Sarne.  A piece of the puzzle: what does BRAF status mean in the management of patients with papillary thyroid carcinoma? , 2012, The Journal of clinical endocrinology and metabolism.

[14]  A. Pinchera,et al.  Modifications in the papillary thyroid cancer gene profile over the last 15 years. , 2012, The Journal of clinical endocrinology and metabolism.

[15]  Zhiyan Liu,et al.  Encapsulated papillary thyroid carcinoma, follicular variant: A misnomer , 2012, Pathology international.

[16]  V. Marotta,et al.  The primary occurrence of BRAF(V600E) is a rare clonal event in papillary thyroid carcinoma. , 2012, The Journal of clinical endocrinology and metabolism.

[17]  Q. Duh,et al.  Higher rate of BRAF mutation in papillary thyroid cancer over time , 2011, Cancer.

[18]  M. Sobrinho-Simões,et al.  Follicular thyroid carcinoma , 2011, Modern Pathology.

[19]  D. Myssiorek,et al.  Improved detection does not fully explain the rising incidence of well-differentiated thyroid cancer: a population-based analysis. , 2010, American journal of surgery.

[20]  Dagmara Rusinek,et al.  Occurrence of BRAF mutations in a Polish cohort of PTC patients - preliminary results. , 2010, Endokrynologia Polska.

[21]  E. Mazzaferri,et al.  Thyroid cancer epidemiology and prognostic variables. , 2010, Clinical oncology (Royal College of Radiologists (Great Britain)).

[22]  I. Colin,et al.  Oxidative stress: a required condition for thyroid cell proliferation. , 2010, The American journal of pathology.

[23]  P. Hou,et al.  Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer. , 2009, The Journal of clinical endocrinology and metabolism.

[24]  Ji Soo Kim,et al.  Clinical and pathological features and the BRAF(V600E) mutation in patients with papillary thyroid carcinoma with and without concurrent Hashimoto thyroiditis. , 2009, Thyroid : official journal of the American Thyroid Association.

[25]  A. Sikora,et al.  The Basis of Racial Differences in the Incidence of Thyroid Cancer , 2008, Annals of Surgical Oncology.

[26]  M. Xing,et al.  BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. , 2007, Endocrine reviews.

[27]  Electron Kebebew,et al.  The Prevalence and Prognostic Value of BRAF Mutation in Thyroid Cancer , 2007, Annals of surgery.

[28]  D. Henson,et al.  Changing Patterns in the Incidence and Survival of Thyroid Cancer with Follicular Phenotype—Papillary, Follicular, and Anaplastic: A Morphological and Epidemiological Study , 2007, Endocrine pathology.

[29]  S. Roman,et al.  Prognosis of medullary thyroid carcinoma , 2006, Cancer.

[30]  P. Ladenson,et al.  BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. , 2005, The Journal of clinical endocrinology and metabolism.

[31]  Elisabeth Cardis,et al.  Risk of thyroid cancer after exposure to 131I in childhood. , 2005, Journal of the National Cancer Institute.

[32]  O. Sheils,et al.  ret/PTC and BRAF Act as Distinct Molecular, Time-Dependant Triggers in a Sporadic Irish Cohort of Papillary Thyroid Carcinoma , 2005, International journal of surgical pathology.

[33]  Z. Szybinski,et al.  A programme of iodine supplementation using only iodised household salt is efficient--the case of Poland. , 2001, European journal of endocrinology.

[34]  Y. Nikiforov,et al.  Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. , 1997, Cancer research.

[35]  A. Belfiore,et al.  Cancer risk in patients with cold thyroid nodules: relevance of iodine intake, sex, age, and multinodularity. , 1992, The American journal of medicine.

[36]  Ó. Bjarnason,et al.  Thyroid cancer in an iodide rich area. A histopathological study , 1977 .

[37]  Z. Szybinski.  Work of the Polish Council for Control of Iodine Deficiency Disorders, and the model of iodine prophylaxis in Poland. , 2012, Endokrynologia Polska.

[38]  P. Calderon,et al.  Oxidative stress in the thyroid gland: from harmlessness to hazard depending on the iodine content. , 2008, Endocrinology.

[39]  M. Gazouli,et al.  BRAF and K-RAS mutation in a Greek papillary and medullary thyroid carcinoma cohort. , 2008, Anticancer research.

[40]  Z. Szybinski,et al.  Iodine-induced hyperthyroidism--an epidemiological survey several years after institution of iodine prophylaxis in Poland. , 2003, Journal of endocrinological investigation.

[41]  Z. Szybinski,et al.  Prevalence of goiter, iodine deficiency and iodine prophylaxis in Poland. The results of a nationwide study. , 1993, Endokrynologia Polska.

[42]  I. Kinalska,et al.  [Results of studies on the effect of radiologic contamination after the Czernobyl catastrophe and prophylactic iodine on thyroid morphology and function of inhabitants of North-East Poland]. , 1991, Endokrynologia Polska.